BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//RE4CH - ECPv6.1.2.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.research-for-children.de
X-WR-CALDESC:Events for RE4CH
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200407T000000
DTEND;TZID=Europe/Berlin:20200407T235959
DTSTAMP:20260819T162701
CREATED:20191210T111317Z
LAST-MODIFIED:20191210T111319Z
UID:1336-1586217600-1586303999@www.research-for-children.de
SUMMARY:Horizon 2020: Coordinating and supporting research on the human microbiome in Europe and beyond
DESCRIPTION:Specific Challenge: \n\n\n\nIntegration\n and application of metagenomics data from the human microbiome has \nshown large potential for personalised medicine approaches\, although \ncausal relationships and confounders are still largely unknown. \nComparable information and details about microbiome composition and \nfunctionality in healthy citizen and patients are very valuable to \ncomplete the picture i.e. to better understand the healthy microbiome \nand to predict its development. \n\n\n\nThe number of European and  international projects and initiatives is increasing but their results  and data cannot be properly compared as they have different underlying  methods\, standards and operating procedures. The International Human  Microbiome Consortium (IHMC) as well as other current initiatives aim to  strengthen international cooperation\, to increase data comparability  and to agree common standards\, procedures and methods. There is a need  to avoid having the same research carried out multiple times at  different places and to better agree at European and at international  level. This collaboration should increase coherence and data  comparability to better exploit existing microbiome data and clinical  information in a standardised way. \n\n\n\n \n\n\n\nFor more information please visit the EC website: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-hco-17-2020
URL:https://www.research-for-children.de/event/horizon-2020-coordinating-and-supporting-research-on-the-human-microbiome-in-europe-and-beyond/
CATEGORIES:Funding Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200407T000000
DTEND;TZID=Europe/Berlin:20200407T235900
DTSTAMP:20260819T162701
CREATED:20191210T111447Z
LAST-MODIFIED:20191210T111732Z
UID:1338-1586217600-1586303940@www.research-for-children.de
SUMMARY:Horizon 2020: Addressing low vaccine uptake
DESCRIPTION:Specific Challenge: \n\n\n\nVaccines\n are one of the most important medical breakthroughs in the last 100 \nyears. Every year vaccines save millions of people around the world from\n illness\, disability and death\, and they continue to be one of the most \ncost-effective ways to increase the health and wellbeing of their \ncitizens. Despite this\, vaccination uptake faces significant challenges \nacross Europe\, and these have increased in particular over the past 20 \nyears. Recent studies have shown Europe to be the world region with the \nmost negative views towards the safety and effectiveness of vaccines\, \nand the importance of childhood vaccination[1]. \n\n\n\nRecent\n figures on collected by the World Health Organization (WHO) show that \nin 2016 only one vaccine had a coverage rate of over 95% in Europe.[2] Seasonal influenza vaccination also remains significantly below the 75% coverage target for older age groups.[3] \n\n\n\nThus\,\n coverage for many vaccines is below the recommended limit. Due to the \nlow vaccine coverage rates\, several EU Member States have faced \nconsiderable outbreaks of vaccine-preventable diseases in recent years. \nFor example\, more than 14\,000 cases of measles were reported across the \nEU in 2017[4]\,\n which is more than three times the number of cases reported in 2016. \nDuring the same period 50 people in the EU died due to measles[5]. \n\n\n\nThese  figures highlight the urgent need to get to grips with vaccine uptake  issues\, whether uptake of existing or new vaccines. Research has an  essential role to play in understanding the underlying causes of poor  vaccine uptake\, including vaccine hesitancy\, and to develop strategies  and guidelines to help Member States and Associated countries increase  vaccination coverage. A detailed understanding of the obstacles to\, and  drivers of\, vaccination uptake in various settings is necessary to  provide appropriate recommendations. \n\n\n\nFor more information please visit the EC webpage: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-bhc-33-2020
URL:https://www.research-for-children.de/event/horizon-2020-addressing-low-vaccine-uptake/
CATEGORIES:Funding Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200407T000000
DTEND;TZID=Europe/Berlin:20200407T235959
DTSTAMP:20260819T162701
CREATED:20191210T111618Z
LAST-MODIFIED:20191210T111621Z
UID:1340-1586217600-1586303999@www.research-for-children.de
SUMMARY:Horizon 2020: Use of Real-World Data to advance research on the management of complex chronic conditions
DESCRIPTION:Specific Challenge: \n\n\n\nThe \nnumber of people with chronic illness is growing and almost half of them\n have multiple chronic conditions. Patients with complex chronic \nconditions (CCCs) have chronic multi-morbidities or chronic disease \ncomplications that require the attention of multiple health care \nproviders or facilities as well as home-based care. A patient with CCC \npresents to the health care system with unique constellation of needs\, \ndisabilities\, or functional limitations[1].  \n\n\n\nManaging\n patients with complex chronic conditions therefore needs approaches \nthat ensure multi-disciplinary\, personalised and well accepted by the \npatient ways of care and monitoring. \n\n\n\nThe controlled randomised \nclinical trials on chronic diseases provide important information that \ncan be translated in the daily clinical practice\, but they often do not \ncomprise sufficient breadth and depth commensurate to the complexity of \ndiseases\, and to the degree of personalisation of treatment needed. \n\n\n\nReal\n World Data (referring specifically to any type of data not collected in\n a randomised clinical trial) can complement these to fill the knowledge\n gap between controlled clinical trials results and clinical practice \nneeds in real environments. They can provide new insights into disease \npatterns and help improve the safety and effectiveness of health \ninterventions.  \n\n\n\nTapping into this rich resource of ‘real world  data’ issued from daily clinical practice\, either collected on a  permanent/regular basis by public bodies or through devices and mobile  applications\, \, and smartly assembled in combination with clinical  studies\, should boost both output and relevance of controlled clinical  research results. \n\n\n\nFor more information please visit the EC website: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/sc1-dth-12-2020
URL:https://www.research-for-children.de/event/horizon-2020-use-of-real-world-data-to-advance-research-on-the-management-of-complex-chronic-conditions/
CATEGORIES:Funding Deadlines
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Berlin:20200407T170000
DTEND;TZID=Europe/Berlin:20200407T170100
DTSTAMP:20260819T162701
CREATED:20190828T075317Z
LAST-MODIFIED:20190828T075458Z
UID:617-1586278800-1586278860@www.research-for-children.de
SUMMARY:Digital diagnostics – developing tools for supporting clinical decisions by integrating various diagnostic data (SC1-BHC-06-2020)
DESCRIPTION:Specific Challenge: \n\n\n\nThe  availability of appropriate decision support tools for healthcare  practitioners can promote uptake of personalised medicine in health  care. There is a need to carry out research activities aiming to develop  and validate such decision tools that would integrate available and/or  emerging diagnostic means for the area concerned\, enabling increased  precision of diagnostics and clinical decision making. On-going progress  in the fields of bioinformatics and biostatistics\, advanced analytical  tools (e.g. machine learning) up to Artificial Intelligence (AI)  solutions\, should make possible the development of devices\, platforms or  novel approaches leading to highly personalised diagnosis\, based on the  integration of data available from various sources. The ultimate result  would be a detailed health status assessment from a multitude of  viewpoints\, in a systemic way and easy to use for clinical purposes\,  leading to better diagnostic accuracy\, increased effectiveness and  efficiency of treatments. Novel hardware enabling truly innovative\,  integrative diagnostic platforms can also be considered.  \n\n\n\nScope: \n\n\n\nProposals should \ndevelop tools\, platforms or services that will use information provided \nby most relevant diagnostic means for a particular area\, resulting in an\n accurate\, detailed\, structured\, systemic and prioritised assessment of \nthe health status in a patient. The proposed solutions should integrate \nvarious data sources such as medical records\, in vitro and/or in vivo\n diagnostics\, medical imaging\, -omics data\, functional tests \n(lab-on-a-chip) etc.\, while taking into account the actual needs of \nhealthcare practitioners\, and should be tested and validated in \nreal-life settings in pilot centres\, facilitating future Health \nTechnology Assessment. These tools/platforms/services should contribute \nto improving diagnosis and clinical decision\, not only integrate \nexisting data\, and should involve intelligent human-computer interface \nsolutions to facilitate its daily use in clinical practice. Any medical \ndata relevant for a particular disease (textual data\, numerical \nmeasurements\, recorded signals\, images etc.) may be considered. The aim \nis to steer the development of solutions towards concrete patient and \npublic sector needs\, having the citizen and healthcare providers at the \ncentre. Careful attention should be paid to appropriately addressing \nethical and legal concerns\, providing adequate information to health \nprofessionals and patients to support informed decisions\, and ensuring \ndata safety and privacy\, in line with existing European and \ninternational standards and legislation. Gender and sex differences \nshould be taken into consideration when relevant. \n\n\n\nThe Commission  considers that proposals requesting a contribution from the EU of  between EUR 8 and 15 million would allow this specific challenge to be  addressed appropriately. Nonetheless\, this does not preclude submission  and selection of proposals requesting different amounts.  \n\n\n\nExpected Impact: \n\n\n\nIncrease  EU’s capacity to innovate in the area of medical instruments  technologies through the development of new diagnostic tools\, platforms  or services integrating various diagnostic data and providing quick\,  detailed\, accurate and highly personalised diagnostics for optimal  decision in clinical practice.Improve the quality and  sustainability of healthcare systems through quicker and more  encompassing diagnosis of medical conditions\, leading to quicker and  better clinical decisions and timely delivery of effective personalised  treatments\, with reduction of errors and delays (and costs associated to  them).Contribute to the growth of the European diagnostics sector\, in particular for SMEs.Reinforce EU’s role among world leaders in the production of medical diagnostic devices.\n\n\n\nFor more information\, please visit the European Commission website.
URL:https://www.research-for-children.de/event/digital-diagnostics-developing-tools-for-supporting-clinical-decisions-by-integrating-various-diagnostic-data-sc1-bhc-06-2020/
CATEGORIES:Funding Deadlines
END:VEVENT
END:VCALENDAR